Financial Services • NYSE
According to Zyberno, DOLBY LABORATORIES, INC. (DLB) is not a buy — GOOD BUSINESS (68/100) with a negative Margin of Safety of +4.5% and a Brina Gap of -16.5% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, DOLBY LABORATORIES, INC. (DLB) trades at $61.50 against an estimated intrinsic value per share of $64.39 — a +4.5% Margin of Safety based on Owner Earnings of $386.02M TTM, projected at 5.4% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -16.5% weakens the case: based on the company's ROIC (7.9%) and reinvestment rate (-31.4%), the business can fundamentally grow at -2.5% — but the current enterprise value implies the market expects 14.0%. This places DLB in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 6.4% annually.
Over the trailing twelve months, DLB generated $386.02M in Owner Earnings. Capital was deployed as follows: $65.00M returned via share buybacks, $134.25M paid as dividends, $34.20M invested in capital expenditures. Reinvestment rate: -31.4%. Owner Earnings have grown at 5.4% annually over the trailing five years using log-linear regression.